Docmorris shares down as weak sales weigh
** Shares of Docmorris DOCM.S fall 2.4% after the Swiss
online drug retailer posts lower H1 sales,
** Co's H1 external revenue falls 21% Y/Y
** EBITDA loss narrows, but in line with estimates
** Co also confirms outlook for 2023
** Stock among worst performers on Swiss mid-cap index
.SMIM
(Reporting by Ozan Ergenay)
((ozan.ergenay@thomsonreuters.com))
Recent news on DocMorris AG
See all newsEurope Research Roundup: Barclays, Societe Generale, UBS Group
Europe Research Roundup: Barclays, Societe Generale, UBS Group
Brief: Shareholder CEPD Says It Rejects DocMorris' Mischaracterisation And Emphasizes Case For Real Governance Reform
DocMorris rises on 'strong' Q1 results
Brief: Docmorris Says Qtrly Revenue Rose By 11.7 Per Cent To CHF 303.8 Million